(Q45966647)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Josh Marehbian

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

H Michael Arrighi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Haijun Tian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

William J Sandborn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

English

0 references

publication date

16 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

The American Journal of Gastroenterology

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

2524-2533

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

Inflammatory bowel disease: clinical aspects and established and evolving therapies

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Long-term evolution of disease behavior of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Management of Crohn's disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Serious adverse events with infliximab: analysis of spontaneously reported adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.322

21 January 2018

Identifiers

DOI

10.1038/AJG.2009.322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19532125%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference